Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies.

Dirks, Bryan; Fava, Maurizio; Atkinson, Sarah D; Joyce, Mark; Thase, Michael E; Howell, Becky; Lin, Tim; Stankovic, Serge

Dirks, Bryan; Fava, Maurizio; Atkinson, Sarah D; Joyce, Mark; Thase, Michael E; Howell, Becky; Lin, Tim; Stankovic, Serge.

Afiliação

Dirks B; Bryan Dirks, Acadia Pharmaceuticals Inc, San Diego, CA, USA.
Fava M; Maurizio Fava, Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Atkinson SD; Sarah D. Atkinson, Evolution Research Group, Rochester, NY, USA.
Joyce M; Mark Joyce, CNS Healthcare, Jacksonville, FL, USA.
Thase ME; Michael E. Thase, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA.
Howell B; Becky Howell, Acadia Pharmaceuticals Inc, Princeton, NJ, USA.
Lin T; Tim Lin, Acadia Pharmaceuticals Inc, San Diego, CA, USA.
Stankovic S; Serge Stankovic, Acadia Pharmaceuticals Inc, San Diego, CA, USA.

Psychopharmacol Bull ; 52(4): 8-30, 2022 10 27.

Article em En | MEDLINE | ID: mdl-36339271

Assuntos

COVID-19; Transtorno Depressivo Maior; Humanos; Transtorno Depressivo Maior/tratamento farmacológico; Método Duplo-Cego; Pandemias; Antidepressivos/efeitos adversos; Resultado do Tratamento

Palavras-chave

MDD; antidepressant agents; anxious depression; controlled study; pharmacotherapy; pimavanserin; randomized

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / COVID-19 Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Psychopharmacol Bull Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google